PMID- 21127695
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Print)
IS  - 1176-6336 (Linking)
VI  - 6
DP  - 2010 Oct 27
TI  - New advances in the treatment of gout: review of pegloticase.
PG  - 543-50
LID - 10.2147/TCRM.S6043 [doi]
AB  - Treatment-failure gout (TFG) affects approximately 50,000 patients or about 1% of 
      the overall population of patients with gout in the United States of America. The 
      severity of TFG is manifested by frequent acute attacks of disabling arthritis, 
      chronic deforming joint disease, destructive masses of urate crystals (tophi), 
      progressive physical disability, and poor health-related quality of life. 
      Pegloticase (Krystexxa((R)); Savient Pharmaceuticals, Inc), a novel PEGylated urate 
      oxidase (uricase) enzyme, has been resubmitted for US Food and Drug 
      Administration approval. In a 6-month, placebo-controlled clinical trial, 8 mg of 
      pegloticase for every 2 weeks induced a lytic decrease of serum urate (sUr) 
      concentrations, leading to dissolution of tophi in 40% of patients at final 
      visit. However, 58% were nonresponders to the defined target sUr of 0.36 mmol/L 
      (80% were nonresponders during months 3 and 6), possibly due to anti-body 
      formation. Also, 26%-31% experienced infusion reactions (IRs) and 77% suffered 
      from gout flares. Although long-term data are awaited, an anti-inflammatory 
      strategy, eg, based on glucocorticosteroids, is needed to prevent pegloticase 
      antibody formation leading to IRs and diminished or shortened efficacy, and might 
      also prevent gout flares. According to the current clinical data, pegloticase 
      might have an important role as a (bridging) treatment in sUr-responsive patients 
      for tophi clearance in severe chronic refractory gout.
FAU - Reinders, Mattheus K
AU  - Reinders MK
AD  - Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands.
FAU - Jansen, Tim L Th A
AU  - Jansen TL
LA  - eng
PT  - Journal Article
DEP - 20101027
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC2988614
OTO - NOTNLM
OT  - PEG-uricase
OT  - gout
OT  - hyperuricemia
OT  - pegloticase
OT  - pharmacotherapy
EDAT- 2010/12/04 06:00
MHDA- 2010/12/04 06:01
PMCR- 2010/10/27
CRDT- 2010/12/04 06:00
PHST- 2010/12/04 06:00 [entrez]
PHST- 2010/12/04 06:00 [pubmed]
PHST- 2010/12/04 06:01 [medline]
PHST- 2010/10/27 00:00 [pmc-release]
AID - tcrm-6-543 [pii]
AID - 10.2147/TCRM.S6043 [doi]
PST - epublish
SO  - Ther Clin Risk Manag. 2010 Oct 27;6:543-50. doi: 10.2147/TCRM.S6043.